Celebrating 25+ years of helping you give wisely
America's most independent,
assertive charity watchdog
Top Rated

EngenderHealth

CharityWatch report issued
February 2021

Top-Rated Charity
A
CharityWatch Grade
Our independent grade based
on a number of factors.
 
76%
Program Percentage
Amount spent on programs
relative to overhead.
 
$2
Cost to Raise $100
Amount spent to raise
$100 of contributions.

Contact Information

EngenderHealth
505 9th Street, NW
Suite 601
Washington, DC, 20004

Other Names

None

Tax Status

501(c)3

Stated Mission

To implement programs that advance sexual & reproductive health & rights and gender equality.

View similar charities
Data based on Fiscal Year Ended 06/30/2019

Program Percentage: 76%

The percentage of EngenderHealth's cash budget it spends on programs relative to overhead (fundraising, management, and general expenses).

$41,000,000

Calculated Total Expenses

(rounded)

 

Cost to Raise $100: $2

How many dollars EngenderHealth spends on fundraising to raise each $100 of contributions.

$14,000,000

Calculated Total Contributions

(rounded)

Government Funding

25% to 49%

Percentage of cash revenue
coming from government sources

 

Financial Documents

Entity Document Type Tax ID
EngenderHealth IRS Form 990 13-1623838
EngenderHealth Audited Financial Statements 13-1623838
Entity: EngenderHealth
Document Type: IRS Form 990
Tax ID: 13-1623838
Entity: EngenderHealth
Document Type: Audited Financial Statements
Tax ID: 13-1623838

Governance & Transparency

CharityWatch evaluates certain criteria related to a charity's Governance and Transparency. Donors may want to consider a charity's willingness to be open and transparent with CharityWatch to be a good litmus test for determining its commitment to public accountability.
This charity is Top-Rated
What does it mean to be Top-Rated?
 
EngenderHealth
meets governance benchmarks.
 
EngenderHealth
meets transparency benchmarks.
Transparency
Provides Financial Information
Audit Accessibility
Governance: Policies
Reports regularly & consistently monitoring & enforcing compliance with a written Conflict of Interest Policy
Reports required, annual disclosure by officers, directors, and key staff of interests that could give rise to conflicts
Reports having a written Whistleblower Policy
Reports having a written Document Retention and Destruction Policy
Governance: Financials
Reports providing copy of tax form to all board members prior to filing it with IRS
Reports that financial statements were audited by an independent accountant
Governance: Board of Directors
Reports at least 5 voting board members
51% or more of voting board members reported as independent
Reports documenting minutes of board and board committee meetings
Privacy Policy
Privacy Policy

  Name Title Compensation
1 Mustafa Kudrati Vice President $338,821
2 Gary Camus Past CFO $312,545
  Note: CFO through 1/24/19
3 Bushra Abbasi Past Project Director $307,044
  Note: Project Director through 11/30/18
1
Name: Mustafa Kudrati
Title: Vice President
Compensation: $338,821
2
Name: Gary Camus
Title: Past CFO
Compensation: $312,545
Note: CFO through 1/24/19
3
Name: Bushra Abbasi
Title: Past Project Director
Compensation: $307,044
Note: Project Director through 11/30/18

CharityWatch Analysts perform an in-depth analysis of charities' audited financial statements and IRS tax filings, and often review other documents such as state filings, annual reports, and fundraising contracts during their evaluations. Below are select notes that CharityWatch believes may be of interest to donors.

According to the EngenderHealth audit of June 30, 2019 (Note 3, Concentration of Credit Risk):

"...Total contributions and private grants revenue received from one donor aggregate to 29% and 71% during 2019 and 2018, respectively..."

According to the EngenderHealth audit of June 30, 2019 (Note 11, Commitments and Contingencies):

"On May 1, 2018, EngenderHealth relocated its headquarters from New York City to Washington, DC. At June 30, 2019, the remaining lease obligation on the New York City office space was $8,386,395. Using third party real estate professionals and appraisers, management estimated potential lease income of $8,166,832 through the remainder of the lease period. At June 30, 2019 and 2018, EngenderHealth estimated the liability on the exit of its rental obligation to be $854,491 and $1,057,940, respectively..."

According to the EngenderHealth audit of June 30, 2019 (Note 16, Management's Discussion of Current Economic Environment and Plan to Improve Results of Operations, re: COVID-19):

"Due to the COVID-19 pandemic, EngenderHealth is expecting a short-term reduction of revenue because some programmatic activities may be delayed while the world addresses this global health crisis. However, EngenderHealth's major donors, both governmental and private, have reached out to express their support and flexibility with their current awards. ... EngenderHealth cannot yet assess the financial impact of program changes due to the pandemic. However, management knows that the need for the work EngenderHealth performs will only be amplified during the COVID-19 response and recovery periods, and management anticipates maintaining and expanding program engagement, especially during the recovery period. With this opportunity and the current support of EngenderHealth's donors to offset short-term challenges, management maintains a strong outlook for fiscal 2020 and 2021."

[...]

"EngenderHealth has taken proactive measures to protect its staff in the US as well as overseas... Staff has pivoted quickly to working from home in the US and in some of EngenderHealth's international offices, moving additional business systems online and ensuring staff are connected by technology. Management is working with EngenderHealth's host country governments to support COVID-19 response efforts and to ensure that its support for sexual and reproductive health services continues uninterrupted...

"Management is also facilitating conversations among EngenderHealth's international non-governmental organization ('NGO') partners, both at the executive level and at the program management level. Through this coordination management is aligning EngenderHealth's policies and practices...to ensure that EngenderHealth's collective staff are safe and supported and its joint projects are protected.

"The COVID-19 pandemic is unprecedented for all of the international NGOs and the governments of the countries where EngenderHealth works. Because of the work EngenderHealth does, management has perspectives and skills that are useful and needed during this time. EngenderHealth is standing with its partners and colleagues in solidarity to ensure a productive response and a swift recovery."

According to the EngenderHealth audit of June 30, 2019 (Note 17, Subsequent Events):

"Subsequent to year end, the COVID-19 pandemic has resulted in substantial volatility in the global financial markets. As a result, EngenderHealth's investment portfolio has incurred a significant decline in its fair value since June 30, 2019. Because the value of EngenderHealth's individual investments have and will fluctuate in response to changing market conditions, the amount of losses, if any, that will be recognized in subsequent periods, cannot be determined."

According to the EngenderHealth (EH) tax filing for the fiscal year ended June 30, 2019, EH reports re: Compensation, Supplemental Information (IRS Form 990, Schedule J, Part III):

Regarding severance payments to officers, directors, trustees, key employees and highest compensated employees (Schedule J, Part I, Line 4a):

"Pursuant to the terms and conditions stipulated in Mr. Richard Killian's severance agreement, the organization paid a severance payment to Mr. Richard Killian in the amount of $50,036 in [calendar year] 2018. The payment was treated as taxable compensation to the recipient.

"Pursuant to the terms and conditions stipulated in Ms. Carmela Cordero's severance agreement, the organization paid a severance payment to Ms. Carmela Cordero in the amount of $107,105 in [calendar year] 2018. The payment was treated as taxable compensation to the recipient.

"Pursuant to the terms and conditions stipulated in Mr. Mark Barone's severance agreement, the organization paid a severance payment to Mr. Mark Barone in the amount of $87,278 in [calendar year] 2018. The payment was treated as taxable compensation to the recipient."


EH reports Richard Killian as "Project Director thru 09/19/18"; Carmela Cordero as "Sr. Clinical Advisor thru 04/30/18"; and Mark Barone as "Sr. Clinical Advisor thru 04/30/18." Their reported total compensation in calendar year 2018 is $233,763; $196,659; and $160,434, respectively (IRS Form 990, Schedule J, Part II).


Related Articles

No related articles found